Insights from 2023 ESMO Annual Meeting


 

ESMO 2023 Insights: "EV-302/KEYNOTE-A39 Study of Enfortumab Vedotin + Pembro vs. Chemo in Previously Untreated la/mUC"

300 views
October 30, 2023
Comments 0
Login to view comments. Click here to Login